The interaction of NK cells and dendritic cells in the tumor environment: How to enforce NK cell & DC action under immunosuppressive conditions?

Current Medicinal Chemistry

Volumn 19, Issue 12, 2012, Pages 1771-1779

  Jacobs, B ^a   Ullrich, E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Dendritic cells; Immune activation; Immune suppression; Immunotherapy; Natural killer cells; Tumor microenvironment

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MANNOSE RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL FUNCTION; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

CELL COMMUNICATION; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84860540844     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800099857     Document Type: Article

References (115)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70. (Pubitemid 30046295)
2. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-74.
3. Pages, F.; Galon, J.; Dieu-Nosjean, M. C.; Tartour, E.; Sautes-Fridman, C.; Fridman, W. H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene, 2010, 29(8), 1093-102.
4. Nelson, B. H. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev, 2008, 222, 101-16. (Pubitemid 351430376)
5. Rosenberg, S. A.; Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol, 2009, 21(2), 233-40.
6. Dudley, S. C., Jr. Ion channelopathies: a tapped-out mine? Am J Physiol Heart Circ Physiol, 2011, 300(3), H716-7.
7. Dudley, M. E.; Yang, J. C.; Sherry, R.; Hughes, M. S.; Royal, R.; Kammula, U.; Robbins, P. F.; Huang, J.; Citrin, D. E.; Leitman, S. F.; Wunderlich, J.; Restifo, N. P.; Thomasian, A.; Downey, S. G.; Smith, F. O.; Klapper, J.; Morton, K.; Laurencot, C.; White, D. E.; Rosenberg, S. A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 2008, 26(32), 5233-9.
8. Porter, D. L.; Levine, B. L.; Kalos, M.; Bagg, A.; June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011, 365(8), 725-33.
9. Kalos, M.; Levine, B. L.; Porter, D. L.; Katz, S.; Grupp, S. A.; Bagg, A.; June, C. H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med, 2011, 3(95), 95ra73.
10. Terakura, S.; Yamamoto, T. N.; Gardner, R. A.; Turtle, C. J.; Jensen, M. C.; Riddell, S. R. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood, 2011.
11. Schuler, G.; Schuler-Thurner, B.; Steinman, R. M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol, 2003, 15(2), 138-47. (Pubitemid 36287518)
12. Svajger, U.; Anderluh, M.; Jeras, M.; Obermajer, N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell Signal, 2010, 22(10), 1397-405.
13. Palucka, K.; Ueno, H.; Banchereau, J. Recent developments in cancer vaccines. J Immunol, 2011, 186(3), 1325-31.
14. Papewalis, C.; Jacobs, B.; Wuttke, M.; Ullrich, E.; Baehring, T.; Fenk, R.; Willenberg, H. S.; Schinner, S.; Cohnen, M.; Seissler, J.; Zacharowski, K.; Scherbaum, W. A.; Schott, M. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol, 2008, 180(3), 1462-70.
15. Pilla, L.; Patuzzo, R.; Rivoltini, L.; Maio, M.; Pennacchioli, E.; Lamaj, E.; Maurichi, A.; Massarut, S.; Marchiano, A.; Santantonio, C.; Tosi, D.; Arienti, F.; Cova, A.; Sovena, G.; Piris, A.; Nonaka, D.; Bersani, I.; Di Florio, A.; Luigi, M.; Srivastava, P. K.; Hoos, A.; Santinami, M.; Parmiani, G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother, 2006, 55(8), 958-68. (Pubitemid 43673585)
16. Kalinski, P.; Edington, H.; Zeh, H. J.; Okada, H.; Butterfield, L. H.; Kirkwood, J. M.; Bartlett, D. L. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res, 2011.
17. Higano, C. S.; Schellhammer, P. F.; Small, E. J.; Burch, P. A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M. W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer, 2009, 115(16), 3670-9.
18. Small, E. J.; Schellhammer, P. F.; Higano, C. S.; Redfern, C. H.; Nemunaitis, J. J.; Valone, F. H.; Verjee, S. S.; Jones, L. A.; Hershberg, R. M. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 2006, 24(19), 3089-94. (Pubitemid 46638945)
19. Sutlu, T.; Alici, E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med, 2009, 266(2), 154-81.
20. Bachanova, V.; Burns, L. J.; McKenna, D. H.; Curtsinger, J.; Panoskaltsis-Mortari, A.; Lindgren, B. R.; Cooley, S.; Weisdorf, D.; Miller, J. S. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother, 2010, 59(11), 1739-44.
21. Miller, J. S.; Soignier, Y.; Panoskaltsis-Mortari, A.; McNearney, S. A.; Yun, G. H.; Fautsch, S. K.; McKenna, D.; Le, C.; Defor, T. E.; Burns, L. J.; Orchard, P. J.; Blazar, B. R.; Wagner, J. E.; Slungaard, A.; Weisdorf, D. J.; Okazaki, I. J.; McGlave, P. B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105(8), 3051-7.
22. Grzywacz, B.; Miller, J. S.; Verneris, M. R. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol, 2008, 21(3), 467-83.
23. Terme, M.; Ullrich, E.; Delahaye, N. F.; Chaput, N.; Zitvogel, L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol, 2008, 9(5), 486-94. (Pubitemid 351560517)
24. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The three Es of cancer immunoediting. Annu Rev Immunol, 2004, 22, 329-60. (Pubitemid 38680426)
25. Steinman, R. M.; Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med, 1973, 137(5), 1142-62.
26. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature, 1998, 392(6673), 245-52. (Pubitemid 28155090)
27. Kurts, C.; Robinson, B. W.; Knolle, P. A. Cross-priming in health and disease. Nat Rev Immunol, 2010, 10(6), 403-14.
28. Kalinski, P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs, 2009, 10(6), 526-35.
29. Mailliard, R. B.; Wankowicz-Kalinska, A.; Cai, Q.; Wesa, A.; Hilkens, C. M.; Kapsenberg, M. L.; Kirkwood, J. M.; Storkus, W. J.; Kalinski, P. alphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res, 2004, 64(17), 5934-7. (Pubitemid 39129387)
30. Muthuswamy, R.; Mueller-Berghaus, J.; Haberkorn, U.; Reinhart, T. A.; Schadendorf, D.; Kalinski, P. PGE (2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood, 2010, 116(9), 1454-9.
31. Kalinski, P.; Schuitemaker, J. H.; Hilkens, C. M.; Wierenga, E. A.; Kapsenberg, M. L. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol, 1999, 162(6), 3231-6. (Pubitemid 29313569)
32. Wong, J. L.; Mailliard, R. B.; Moschos, S. J.; Edington, H.; Lotze, M. T.; Kirkwood, J. M.; Kalinski, P. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother, 2011, 34(3), 270-8.
33. Mailliard, R. B.; Son, Y. I.; Redlinger, R.; Coates, P. T.; Giermasz, A.; Morel, P. A.; Storkus, W. J.; Kalinski, P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol, 2003, 171(5), 2366-73. (Pubitemid 37025543)
34. Kalinski, P.; Urban, J.; Narang, R.; Berk, E.; Wieckowski, E.; Muthuswamy, R. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol, 2009, 5(3), 379-90.
35. Fujita, M.; Zhu, X.; Ueda, R.; Sasaki, K.; Kohanbash, G.; Kastenhuber, E. R.; McDonald, H. A.; Gibson, G. A.; Watkins, S. C.; Muthuswamy, R.; Kalinski, P.; Okada, H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res, 2009, 69(4), 1587-95.
36. Okada, H.; Kalinski, P.; Ueda, R.; Hoji, A.; Kohanbash, G.; Donegan, T. E.; Mintz, A. H.; Engh, J. A.; Bartlett, D. L.; Brown, C. K.; Zeh, H.; Holtzman, M. P.; Reinhart, T. A.; Whiteside, T. L.; Butterfield, L. H.; Hamilton, R. L.; Potter, D. M.; Pollack, I. F.; Salazar, A. M.; Lieberman, F. S. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol, 2011, 29(3), 330-6.
37. Wieckowski, E.; Chatta, G. S.; Mailliard, R. M.; Gooding, W.; Palucka, K.; Banchereau, J.; Kalinski, P. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8 (+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate, 2011, 71(2), 125-33.
38. Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den Driesch, P.; Brocker, E. B.; Steinman, R. M.; Enk, A.; Kampgen, E.; Schuler, G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med, 1999, 190(11), 1669-78. (Pubitemid 30002348)
39. Schuler-Thurner, B.; Dieckmann, D.; Keikavoussi, P.; Bender, A.; Maczek, C.; Jonuleit, H.; Roder, C.; Haendle, I.; Leisgang, W.; Dunbar, R.; Cerundolo, V.; von Den Driesch, P.; Knop, J.; Brocker, E. B.; Enk, A.; Kampgen, E.; Schuler, G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol, 2000, 165(6), 3492-6.
40. Connerotte, T.; Van Pel, A.; Godelaine, D.; Tartour, E.; Schuler-Thurner, B.; Lucas, S.; Thielemans, K.; Schuler, G.; Coulie, P. G. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res, 2008, 68(10), 3931-40.
41. Banchereau, J.; Palucka, A. K.; Dhodapkar, M.; Burkeholder, S.; Taquet, N.; Rolland, A.; Taquet, S.; Coquery, S.; Wittkowski, K. M.; Bhardwaj, N.; Pineiro, L.; Steinman, R.; Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res, 2001, 61(17), 6451-8. (Pubitemid 32783251)
42. Palucka, A. K.; Ueno, H.; Connolly, J.; Kerneis-Norvell, F.; Blanck, J. P.; Johnston, D. A.; Fay, J.; Banchereau, J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother, 2006, 29(5), 545-57. (Pubitemid 44395279)
43. Kiessling, R.; Klein, E.; Wigzell, H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol, 1975, 5(2), 112-7.
44. Moretta, L.; Ferlazzo, G.; Bottino, C.; Vitale, M.; Pende, D.; Mingari, M. C.; Moretta, A. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev, 2006, 214, 219-28. (Pubitemid 44707913)
45. Ljunggren, H. G.; Karre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today, 1990, 11(7), 237-44. (Pubitemid 20198988)
46. Champsaur, M.; Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev, 2010, 235(1), 267-85.
47. Vivier, E.; Raulet, D. H.; Moretta, A.; Caligiuri, M. A.; Zitvogel, L.; Lanier, L. L.; Yokoyama, W. M.; Ugolini, S. Innate or adaptive immunity? The example of natural killer cells. Science, 2011, 331(6013), 44-9.
48. Ferlazzo, G.; Tsang, M. L.; Moretta, L.; Melioli, G.; Steinman, R. M.; Munz, C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med, 2002, 195(3), 343-51. (Pubitemid 34461492)
49. Ullrich, E.; Menard, C.; Flament, C.; Terme, M.; Mignot, G.; Bonmort, M.; Plumas, J.; Chaperot, L.; Chaput, N.; Zitvogel, L. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev, 2008, 19(1), 79-92.
50. Walzer, T.; Dalod, M.; Vivier, E.; Zitvogel, L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther, 2005, 5 Suppl 1, S49-59. (Pubitemid 41243345)
51. Walzer, T.; Dalod, M.; Robbins, S. H.; Zitvogel, L.; Vivier, E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood, 2005, 106(7), 2252-8. (Pubitemid 41510793)
52. Moretta, A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol, 2002, 2(12), 957-64. (Pubitemid 37323216)
53. Vitale, M.; Della Chiesa, M.; Carlomagno, S.; Romagnani, C.; Thiel, A.; Moretta, L.; Moretta, A. The small subset of CD56brightCD16-natural killer cells is selectively responsible for both cell proliferation and interferongamma production upon interaction with dendritic cells. Eur J Immunol, 2004, 34(6), 1715-22. (Pubitemid 39256054)
54. Piccioli, D.; Sbrana, S.; Melandri, E.; Valiante, N. M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med, 2002, 195(3), 335-41. (Pubitemid 34461491)
55. Ferlazzo, G.; Pack, M.; Thomas, D.; Paludan, C.; Schmid, D.; Strowig, T.; Bougras, G.; Muller, W. A.; Moretta, L.; Munz, C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A, 2004, 101(47), 16606-11. (Pubitemid 39557760)
56. Gerosa, F.; Baldani-Guerra, B.; Nisii, C.; Marchesini, V.; Carra, G.; Trinchieri, G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med, 2002, 195(3), 327-33. (Pubitemid 34461490)
57. Brilot, F.; Strowig, T.; Roberts, S. M.; Arrey, F.; Munz, C. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J Clin Invest, 2007, 117(11), 3316-29. (Pubitemid 350096988)
58. Vujanovic, L.; Szymkowski, D. E.; Alber, S.; Watkins, S. C.; Vujanovic, N. L.; Butterfield, L. H. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membranebound TNF and IL-15. Blood, 2010, 116(4), 575-83.
59. Semino, C.; Angelini, G.; Poggi, A.; Rubartelli, A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood, 2005, 106(2), 609-16. (Pubitemid 40981258)
60. Jinushi, M.; Takehara, T.; Kanto, T.; Tatsumi, T.; Groh, V.; Spies, T.; Miyagi, T.; Suzuki, T.; Sasaki, Y.; Hayashi, N. Critical role of MHC class Irelated chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol, 2003, 170(3), 1249-56. (Pubitemid 36139490)
61. Draghi, M.; Pashine, A.; Sanjanwala, B.; Gendzekhadze, K.; Cantoni, C.; Cosman, D.; Moretta, A.; Valiante, N. M.; Parham, P. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol, 2007, 178(5), 2688-98. (Pubitemid 46333145)
62. Della Chiesa, M.; Vitale, M.; Carlomagno, S.; Ferlazzo, G.; Moretta, L.; Moretta, A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol, 2003, 33(6), 1657-66. (Pubitemid 36790427)
63. Pende, D.; Castriconi, R.; Romagnani, P.; Spaggiari, G. M.; Marcenaro, S.; Dondero, A.; Lazzeri, E.; Lasagni, L.; Martini, S.; Rivera, P.; Capobianco, A.; Moretta, L.; Moretta, A.; Bottino, C. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood, 2006, 107(5), 2030-6. (Pubitemid 43289387)
64. Karimi, K.; Boudreau, J. E.; Fraser, K.; Liu, H.; Delanghe, J.; Gauldie, J.; Xing, Z.; Bramson, J. L.; Wan, Y. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther, 2008, 16(2), 411-8. (Pubitemid 351168051)
65. Hayakawa, Y.; Smyth, M. J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol, 2006, 176(3), 1517-24. (Pubitemid 43134295)
66. Fricke, I.; Gabrilovich, D. I. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest, 2006, 35(3-4), 459-83. (Pubitemid 44266783)
67. Puri, A.; Dudley, E. G. Influence of indigenous eukaryotic microbial communities on the reduction of Escherichia coli O157: H7 in compost slurry. FEMS Microbiol Lett, 2010, 313(2), 148-54.
68. Fukumori, T.; Takenaka, Y.; Yoshii, T.; Kim, H. R.; Hogan, V.; Inohara, H.; Kagawa, S.; Raz, A. CD29 and CD7 mediate galectin-3-induced type II Tcell apoptosis. Cancer Res, 2003, 63(23), 8302-11. (Pubitemid 37549482)
69. Shekhar, M. P.; Nangia-Makker, P.; Tait, L.; Miller, F.; Raz, A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol, 2004, 165(6), 1931-41. (Pubitemid 39578372)
70. Yu, F.; Finley, R. L., Jr.; Raz, A.; Kim, H. R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem, 2002, 277(18), 15819-27. (Pubitemid 34967860)
71. Suliman, A.; Lam, A.; Datta, R.; Srivastava, R. K. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene, 2001, 20(17), 2122-33. (Pubitemid 32424006)
72. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141(1), 52-67.
73. Parks, W. C.; Wilson, C. L.; Lopez-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol, 2004, 4(8), 617-29. (Pubitemid 39025047)
74. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2002, 2(3), 161-74. (Pubitemid 37328786)
75. Liotta, L. A.; Tryggvason, K.; Garbisa, S.; Hart, I.; Foltz, C. M.; Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 1980, 284(5751), 67-8. (Pubitemid 10098769)
76. Gutierrez-Fernandez, A.; Fueyo, A.; Folgueras, A. R.; Garabaya, C.; Pennington, C. J.; Pilgrim, S.; Edwards, D. R.; Holliday, D. L.; Jones, J. L.; Span, P. N.; Sweep, F. C.; Puente, X. S.; Lopez-Otin, C. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res, 2008, 68(8), 2755-63. (Pubitemid 351556273)
77. Palavalli, L. H.; Prickett, T. D.; Wunderlich, J. R.; Wei, X.; Burrell, A. S.; Porter-Gill, P.; Davis, S.; Wang, C.; Cronin, J. C.; Agrawal, N. S.; Lin, J. C.; Westbroek, W.; Hoogstraten-Miller, S.; Molinolo, A. A.; Fetsch, P.; Filie, A. C.; O'Connell, M. P.; Banister, C. E.; Howard, J. D.; Buckhaults, P.; Weeraratna, A. T.; Brody, L. C.; Rosenberg, S. A.; Samuels, Y. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet, 2009, 41(5), 518-20.
78. Fidler, I. J.; Schroit, A. J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta, 1988, 948(2), 151-73. (Pubitemid 18263873)
79. Ryder, M.; Ghossein, R. A.; Ricarte-Filho, J. C.; Knauf, J. A.; Fagin, J. A. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer, 2008, 15(4), 1069-74.
80. Li, Y. W.; Qiu, S. J.; Fan, J.; Gao, Q.; Zhou, J.; Xiao, Y. S.; Xu, Y.; Wang, X. Y.; Sun, J.; Huang, X. W. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol, 2009, 135(3), 439-49.
81. Biswas, S. K.; Gangi, L.; Paul, S.; Schioppa, T.; Saccani, A.; Sironi, M.; Bottazzi, B.; Doni, A.; Vincenzo, B.; Pasqualini, F.; Vago, L.; Nebuloni, M.; Mantovani, A.; Sica, A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood, 2006, 107(5), 2112-22. (Pubitemid 43289397)
82. Qian, B. Z.; Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141(1), 39-51.
83. Sakaguchi, S.; Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T. Regulatory T cells: how do they suppress immune responses? Int Immunol, 2009, 21(10), 1105-11.
84. Cao, X.; Cai, S. F.; Fehniger, T. A.; Song, J.; Collins, L. I.; Piwnica-Worms, D. R.; Ley, T. J. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 2007, 27(4), 635-46. (Pubitemid 47628832)
85. Paust, S.; Lu, L.; McCarty, N.; Cantor, H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A, 2004, 101(28), 10398-403. (Pubitemid 38924937)
86. Gabrilovich, D. I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 2009, 9(3), 162-74.
87. Nagaraj, S.; Gabrilovich, D. I. Myeloid-derived suppressor cells in human cancer. Cancer J, 2010, 16(4), 348-53.
88. Serafini, P.; Mgebroff, S.; Noonan, K.; Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res, 2008, 68(13), 5439-49.
89. Li, H.; Han, Y.; Guo, Q.; Zhang, M.; Cao, X. Cancer-expanded myeloidderived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 2009, 182(1), 240-9.
90. Hoechst, B.; Voigtlaender, T.; Ormandy, L.; Gamrekelashvili, J.; Zhao, F.; Wedemeyer, H.; Lehner, F.; Manns, M. P.; Greten, T. F.; Korangy, F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 2009, 50(3), 799-807.
91. Ghiringhelli, F.; Menard, C.; Terme, M.; Flament, C.; Taieb, J.; Chaput, N.; Puig, P. E.; Novault, S.; Escudier, B.; Vivier, E.; Lecesne, A.; Robert, C.; Blay, J. Y.; Bernard, J.; Caillat-Zucman, S.; Freitas, A.; Tursz, T.; Wagner-Ballon, O.; Capron, C.; Vainchencker, W.; Martin, F.; Zitvogel, L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 2005, 202(8), 1075-85. (Pubitemid 41464501)
92. Giroux, M.; Yurchenko, E.; St-Pierre, J.; Piccirillo, C. A.; Perreault, C. T regulatory cells control numbers of NK cells and CD8alpha+ immature dendritic cells in the lymph node paracortex. J Immunol, 2007, 179(7), 4492-502.
93. Nausch, N.; Galani, I. E.; Schlecker, E.; Cerwenka, A. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood, 2008, 112(10), 4080-9.
94. Stojanovic, A.; Cerwenka, A. Natural killer cells and solid tumors. J Innate Immun, 2011, 3(4), 355-64.
95. Coudert, J. D.; Scarpellino, L.; Gros, F.; Vivier, E.; Held, W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood, 2008, 111(7), 3571-8.
96. Balsamo, M.; Scordamaglia, F.; Pietra, G.; Manzini, C.; Cantoni, C.; Boitano, M.; Queirolo, P.; Vermi, W.; Facchetti, F.; Moretta, A.; Moretta, L.; Mingari, M. C.; Vitale, M. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A, 2009, 106(49), 20847-52.
97. Salih, H. R.; Rammensee, H. G.; Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol, 2002, 169(8), 4098-102. (Pubitemid 35178177)
98. Kaiser, B. K.; Yim, D.; Chow, I. T.; Gonzalez, S.; Dai, Z.; Mann, H. H.; Strong, R. K.; Groh, V.; Spies, T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature, 2007, 447(7143), 482-6. (Pubitemid 46816733)
99. Della Chiesa, M.; Carlomagno, S.; Frumento, G.; Balsamo, M.; Cantoni, C.; Conte, R.; Moretta, L.; Moretta, A.; Vitale, M. The tryptophan catabolite Lkynurenine inhibits the surface expression of NKp46-and NKG2Dactivating receptors and regulates NK-cell function. Blood, 2006, 108(13), 4118-25. (Pubitemid 44913283)
100. Castriconi, R.; Cantoni, C.; Della Chiesa, M.; Vitale, M.; Marcenaro, E.; Conte, R.; Biassoni, R.; Bottino, C.; Moretta, L.; Moretta, A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A, 2003, 100(7), 4120-5. (Pubitemid 36418167)
101. Ma, Y.; Aymeric, L.; Locher, C.; Kroemer, G.; Zitvogel, L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol, 2011, 23(1), 146-52.
102. Villablanca, E. J.; Raccosta, L.; Zhou, D.; Fontana, R.; Maggioni, D.; Negro, A.; Sanvito, F.; Ponzoni, M.; Valentinis, B.; Bregni, M.; Prinetti, A.; Steffensen, K. R.; Sonnino, S.; Gustafsson, J. A.; Doglioni, C.; Bordignon, C.; Traversari, C.; Russo, V. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med, 2010, 16(1), 98-105.
103. Herber, D. L.; Cao, W.; Nefedova, Y.; Novitskiy, S. V.; Nagaraj, S.; Tyurin, V. A.; Corzo, A.; Cho, H. I.; Celis, E.; Lennox, B.; Knight, S. C.; Padhya, T.; McCaffrey, T. V.; McCaffrey, J. C.; Antonia, S.; Fishman, M.; Ferris, R. L.; Kagan, V. E.; Gabrilovich, D. I. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med, 2010, 16(8), 880-6.
104. Hartmann, E.; Wollenberg, B.; Rothenfusser, S.; Wagner, M.; Wellisch, D.; Mack, B.; Giese, T.; Gires, O.; Endres, S.; Hartmann, G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res, 2003, 63(19), 6478-87. (Pubitemid 37255200)
105. Cao, W.; Bover, L.; Cho, M.; Wen, X.; Hanabuchi, S.; Bao, M.; Rosen, D. B.; Wang, Y. H.; Shaw, J. L.; Du, Q.; Li, C.; Arai, N.; Yao, Z.; Lanier, L. L.; Liu, Y. J. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med, 2009, 206(7), 1603-14.
106. Terme, M.; Chaput, N.; Combadiere, B.; Ma, A.; Ohteki, T.; Zitvogel, L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol, 2008, 180(7), 4679-86.
107. Mailliard, R. B.; Alber, S. M.; Shen, H.; Watkins, S. C.; Kirkwood, J. M.; Herberman, R. B.; Kalinski, P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med, 2005, 202(7), 941-53.
108. Van Elssen, C. H.; Vanderlocht, J.; Oth, T.; Senden-Gijsbers, B. L.; Germeraad, W. T.; Bos, G. M. Inflammation restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood, 2011, 118(9), 2473-82.
109. Scheier, B.; Amaria, R.; Lewis, K.; Gonzalez, R. Novel therapies in melanoma. Immunotherapy, 2011, 3(12), 1461-9.
110. Qureshi, O. S.; Zheng, Y.; Nakamura, K.; Attridge, K.; Manzotti, C.; Schmidt, E. M.; Baker, J.; Jeffery, L. E.; Kaur, S.; Briggs, Z.; Hou, T. Z.; Futter, C. E.; Anderson, G.; Walker, L. S.; Sansom, D. M. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science, 2011, 332(6029), 600-3.
111. Apetoh, L.; Vegran, F.; Ladoire, S.; Ghiringhelli, F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med, 2011, 11(5), 365-72.
112. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007, 13(9), 1050-9. (Pubitemid 47517504)
113. Obeid, M.; Tesniere, A.; Panaretakis, T.; Tufi, R.; Joza, N.; van Endert, P.; Ghiringhelli, F.; Apetoh, L.; Chaput, N.; Flament, C.; Ullrich, E.; de Botton, S.; Zitvogel, L.; Kroemer, G. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev, 2007, 220, 22-34. (Pubitemid 350045569)
114. Suzuki, E.; Kapoor, V.; Jassar, A. S.; Kaiser, L. R.; Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res, 2005, 11(18), 6713-21. (Pubitemid 41339014)
115. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rebe, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res, 2010, 70(8), 3052-61.